- Home
- ATLC vs AKBA Comparison
ATLC vs AKBA Comparison
Compare ATLC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- AKBA
- Stock Information
- Founded
- ATLC 1996
- AKBA 2007
- Country
- ATLC United States
- AKBA United States
- Employees
- ATLC N/A
- AKBA N/A
- Industry
- ATLC Finance: Consumer Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- ATLC Finance
- AKBA Health Care
- Exchange
- ATLC Nasdaq
- AKBA Nasdaq
- Market Cap
- ATLC 816.9M
- AKBA 729.1M
- IPO Year
- ATLC 1999
- AKBA 2014
- Fundamental
- Price
- ATLC $52.03
- AKBA $1.86
- Analyst Decision
- ATLC Buy
- AKBA Strong Buy
- Analyst Count
- ATLC 7
- AKBA 6
- Target Price
- ATLC $78.71
- AKBA $6.25
- AVG Volume (30 Days)
- ATLC 68.7K
- AKBA 5.7M
- Earning Date
- ATLC 11-10-2025
- AKBA 11-10-2025
- Dividend Yield
- ATLC N/A
- AKBA N/A
- EPS Growth
- ATLC 26.57
- AKBA N/A
- EPS
- ATLC 5.63
- AKBA N/A
- Revenue
- ATLC $498,496,000.00
- AKBA $225,071,000.00
- Revenue This Year
- ATLC $367.57
- AKBA $53.38
- Revenue Next Year
- ATLC $35.94
- AKBA $30.53
- P/E Ratio
- ATLC $9.19
- AKBA N/A
- Revenue Growth
- ATLC 33.26
- AKBA 32.49
- 52 Week Low
- ATLC $41.37
- AKBA $1.52
- 52 Week High
- ATLC $78.91
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- ATLC 40.01
- AKBA 32.18
- Support Level
- ATLC $48.74
- AKBA $1.57
- Resistance Level
- ATLC $58.59
- AKBA $3.19
- Average True Range (ATR)
- ATLC 2.74
- AKBA 0.16
- MACD
- ATLC -0.31
- AKBA -0.07
- Stochastic Oscillator
- ATLC 25.75
- AKBA 17.34
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.